Fosamax ONJ Problems Could Occur in 4% of Users After Dental Procedures
Although Merck & Co. has suggested that Fosamax side effects do not increase the risk of osteonecrosis of the jaw (ONJ), or only present a negligible risk, recent research has found that about 4% of users developed Fosamax ONJ problems, and the risk was seen even with short-term use after certain dental procedures were performed.
>>INFORMATION: Fosamax Jaw Lawsuits
Fosamax (alendronate sodium) is an oral bisphosphonate that is prescribed to treat osteoporosis by increasing bone density and reducing the risk of fractures. However, it has been linked to debilitating jaw problems, where the jaw bone actually decays and dies.
Known as osteonecrosis of the jaw, ONJ or jaw necrosis, this side effect of Fosamax is irreversible and debilitating. It could result in exposed areas of bone inside the mouth and may lead to the need for surgery to remove portions of the jaw.
A study published earlier this year in the Journal of the American Dental Association was the first large institutional study regarding the use of Fosamax and ONJ. Researchers found that 9 out of the 208 participants who used oral bisphosphonates for any length of time developed ONJ. This is over 4%, or about 1 in 25 patients, which is substantially higher than Merck would want users to believe.
FOSAMAX ONJ LAWSUITS
The Fosamax lawyers at Saiontz & Kirk, P.A. represent individuals throughout the United States who have been diagnosed with this disfiguring jaw condition.
Potential lawsuits are still being reviewed for those who suspect that they, a friend or family member may be suffering from Fosamax ONJ problems. Free consultations and claim evaluations are provided to help determine if financial compensation may be available from Merck for failing to warn about the risk, and there are no fees or expenses unless a recovery is obtained.
To review a potential case with our attorneys, request a free Fosamax ONJ lawsuit consultation.
